Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2021 | The future of MPN therapy

Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center, Tampa, FL, comments on the direction in which myeloproliferative neoplasm (MPN) therapy is currently headed and the implications for MPN patients. Dr Kuykendall talks on the currently approved treatments ruxolitinib and fedratinib, and the patient subgroups whose clinical needs are not well served by JAK inhibition. Dr Kuykendall also talks about a potential shift in research focus which may be witnessed in the coming years, centered around early intervention in the chronic phases of MPNs to halt disease progression. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.

Disclosures

Andrew Kuykendall, MD, has received research fees from Protagonist, Sierra and Prelude; has participated in steering committees for Constellation and Protagonist; has participated in consultancy for Protagonist; has received honoraria from and/or participated in advisory boards with Pharmaessentia, BMS/Celgene, Incyte, Novartis, Abbvie and Blueprint; and has participated in speakers’ bureau for Novartis, Blueprint and BMS/Celgene.